Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Eli Lilly and Co. will pay at least $7 million to acquire rights to a diabetes compound developed by Toronto-based Transition Therapeutics Inc., the companies announced tonight.
Indianapolis-based Lilly will work with Transition to complete a Phase II trial of a compound called TT-223, which provided sustained improvement in blood sugar control during preclinical studies.
Under the terms of the agreement, Lilly could pay Transition up to $130 million if the company achieves certain development and sales goals. Transition would also receive royalties from any future commercial sales.
Please enable JavaScript to view this content.